Document is current
Any future updates will be listed below
-
Authors
Chin, Jie Fen
Aga, Yaar S.
Abou Kamar, Sabrina
Snelder, Sanne M
Verloop, Willemien L
Kardys, Isabella
Brugts, Jasper J
de Boer, Rudolf A.
van Dalen, Bas M.
-
Funding
Funding for this research was provided by:
Stichting BeterKeten
Stichting Onderzoek Franciscus
- License Information
-
More Information
Article History
Received: 14 July 2025
Revised: 27 October 2025
Accepted: 10 November 2025
First Online: 29 December 2025
Declarations
:
: The authors confirm that patient consent forms have been obtained for this article.
: The institution of Dr. De Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Dr. de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Dr. de Boer received travel support from Abbott and NovoNordisk. Dr. Kardys received travel reimbursement from Olink and SomaLogic. The institution of Dr. Van Dalen received research grants from Biotronik SE & Co. KG, Boehringer Ingelheim, Pfizer, Daiichi Sankyo, Sanofi and Novo Nordisk. Dr Brugts reports speaker engagement with Astra Zeneca, Abbott, Bayer, Boehringer, Novartis and Vifor in the past 5 years not related to the current work. The remaining authors report no relationships that could be construed as a conflict of interest.
